In particular, tau pathology has been linked to a greater LP burden [33,37,52] and was the only co-pathology considered when interpreting neuropathological findings in DLB that were recognized in the DLB guidelines [1,53]. The gene discussed is MAPT; the disease is Lewy body dementia.